![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 43
2023
Weiss, L.; Heinrich, K.; Zhang, D.; Dorman, K.; Rühlmann, K.; Hasselmann, K.; Klauschen, F.; Kumbrink, J.; Jung, A.; Rudelius, M.; Mock, A.; Ormanns, Steffen 
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
2022
Janning, M.; Sueptitz, J.; Albers-Leischner, C.; Delpy, P.; Tufman, Amanda; Velthaus-Rusik, J.-L.; Reck, M.; Jung, A.; Kauffmann-Guerrero, Diego ORCID: https://orcid.org/0000-0003-1471-3290; Bonzheim, I.; Braendlein, S.; Hummel, H.-D.; Wiesweg, M.; Schildhaus, H.-U.; Stratmann, J. A.; Sebastian, M.; Alt, J.; Buth, J.; Esposito, I.; Berger, J.; Toegel, L.; Saalfeld, F. C.; Wermke, M.; Merkelbach-Bruse, S.; Hillmer, A. M.; Klauschen, F.; Bokemeyer, C.; Buettner, R.; Wolf, J. und Loges, S.
(2022):
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM).
In: Annals of Oncology, Bd. 33, Nr. 6: S. 602-615
ORCID: https://orcid.org/0000-0003-1471-3290; Bonzheim, I.; Braendlein, S.; Hummel, H.-D.; Wiesweg, M.; Schildhaus, H.-U.; Stratmann, J. A.; Sebastian, M.; Alt, J.; Buth, J.; Esposito, I.; Berger, J.; Toegel, L.; Saalfeld, F. C.; Wermke, M.; Merkelbach-Bruse, S.; Hillmer, A. M.; Klauschen, F.; Bokemeyer, C.; Buettner, R.; Wolf, J. und Loges, S.
(2022):
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM).
In: Annals of Oncology, Bd. 33, Nr. 6: S. 602-615
2020
Ortiz-Brüchle, N.; Muders, M.; Toma, M.; Esposito, I; Hartmann, A.; Stöhr, R.; Reis, H.; Wild, P.; Köllermann, J.; Bremmer, F.; Leichsenring, J.; Stenzinger, A.; Merkelbach-Bruse, S.; Kirfel, S.; Perner, S.; Hartmann, N.; Roth, W.; Jung, A.; Kirchner, T.; Schwamborn, K.; Pfarr, N.; Dahl, E.; Knüchel, R. und Gaisa, N. T.
(2020):
Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie.
In: Urologe, Bd. 59, Nr. 3: S. 318-325
2019
Pinto, A.; Adams, S.; Ahring, K.; Allen, H.; Almeida, M. F.; Garcia-Arenas, D.; Arslan, N.; Assoun, M.; Altinok, Y. Atik; Barrio-Carreras, D.; Quintana, A. Belanger; Bernabei, S. M.; Bontemps, C.; Boyle, F.; Bruni, G.; Bueno-Delgado, M.; Caine, G.; Carvalho, R.; Chrobot, A.; Chyz, K.; Cochrane, B.; Correia, C.; Corthouts, K.; Daly, A.; De Leo, S.; Desloovere, A.; De Meyer, A.; De Theux, A.; Didycz, B.; Dijsselhof, M. E.; Dokoupil, K.; Drabik, J.; Dunlop, C.; Eberle-Pelloth, W.; Eftring, K.; Ekengrena, J.; Errekalde, I.; Evans, S.; Foucart, A.; Fokkema, L.; Francois, L.; French, M.; Forssell, E.; Gingell, C.; Goncalves, C.; Ozel, H. Gokmen; Grimsley, A.; Gugelmo, G.; Gyure, E.; Heller, C.; Hensler, R.; Jardim, I.; Joost, C.; Jörg-Streller, M.; Jouault, C.; Jung, A.; Kanthe, M.; Koc, N.; Kok, I. L.; Kozanoglu, T.; Kumru, B.; Lang, F.; Lang, K.; Liegeois, I.; Liguori, A.; Lilje, R.; Lubina, O.; Manta-Vogli, P.; Mayr, D.; Meneses, C.; Newby, C.; Meyer, U.; Mexia, S.; Nicol, C.; Och, U.; Olivas, S. M.; Pedron-Giner, C.; Pereira, R.; Plutowska-Hoffmann, K.; Purves, J.; Dionigi, A. Re; Reinson, K.; Robert, M.; Robertson, L.; Rocha, J. C.; Rohde, C.; Rosenbaum-Fabian, S.; Rossi, A.; Ruiz, M.; Saligova, J.; Gutierrez-Sanchez, A.; Schlune, A.; Schulpis, K.; Serrano-Nieto, J.; Skarpalezou, A.; Skeath, R.; Slabbert, A.; Straczek, K.; Gizewska, M.; Terry, A.; Thom, R.; Tooke, A.; Tuokkola, J.; van Dam, E.; van den Hurk, T. A. M.; van der Ploegcn, E. M. C.; Kerckhove, K. Vande; Van Driessche, M.; van Wegberg, A. M. J.; van Wyk, K.; Vasconcelos, C.; Garcia, V. Velez; Wildgoose, J.; Winkler, T.; Zolkowska, J.; Zuvadelli, J. und MacDonald, A.
(2019):
Weaning practices in phenylketonuria vary between health professionals in Europe.
In: Molecular Genetics and Metabolism Reports, Bd. 18: S. 39-44
Stintzing, S.; Wirapati, P.; Lenz, H. J.; Neureiter, D.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Moehler, M.; Scheithauer, W.; Held, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Aderka, D.; Tejpar, S. und Heinemann, V
(2019):
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 30, Nr. 11: S. 1796-1803
2018
Hirsch, B.; Endris, V.; Lassmann, S.; Weichert, W.; Pfarr, N.; Schirmacher, P.; Kovaleva, V.; Werner, M.; Bonzheim, I.; Fend, F.; Sperveslage, J.; Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.; Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.; Weidner, S.; Jung, A.; Kirchner, T.; Hansmann, M. L.; Burbat, L.; Wall, E. von der; Dietel, M. und Hummel, M.
(2018):
Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
In: Virchows Archiv, Bd. 472, Nr. 4: S. 557-565
Pinto, A.; Adams, S.; Ahring, K.; Allen, H.; Almeida, M. F.; Garcia-Arenas, D.; Arslan, N.; Assoun, M.; Altinok, Y. Atik; Barrio-Carreras, D.; Belanger Quintana, A.; Bernabei, S. M.; Bontemps, C.; Boyle, F.; Bruni, G.; Bueno-Delgado, M.; Caine, G.; Carvalho, R.; Chrobot, A.; Chyz, K.; Cochrane, B.; Correia, C.; Corthouts, K.; Daly, A.; Leo, S. de; Desloovere, A.; Meyer, A. de; Theux, A. de; Didycz, B.; Dijsselhof, M. E.; Dokoupil, K.; Drabik, J.; Dunlop, C.; Eberle-Pelloth, W.; Eftring, K.; Ekengren, J.; Errekalde, I.; Evans, S.; Foucart, A.; Fokkema, L.; Francois, L.; French, M.; Forssell, E.; Gingell, C.; Goncalves, C.; Ozel, H. Gokmen; Grimsley, A.; Gugelmo, G.; Gyure, E.; Heller, C.; Hensler, R.; Jardim, I.; Joost, C.; Jörg-Streller, M.; Jouault, C.; Jung, A.; Kanthe, M.; Koc, N.; Kok, I. L.; Kozanoglu, T.; Kumru, B.; Lang, F.; Lang, K.; Liegeois, I.; Liguori, A.; Lilje, R.; Lubina, O.; Manta-Vogli, P.; Mayr, D.; Meneses, C.; Newby, C.; Meyer, U.; Mexia, S.; Nicol, C.; Och, U.; Olivas, S. M.; Pedron-Giner, C.; Pereira, R.; Plutowska-Hoffmann, K.; Purves, J.; Dionigi, A. Re; Reinson, K.; Robert, M.; Robertson, L.; Rocha, J. C.; Rohde, C.; Rosenbaum-Fabian, S.; Rossi, A.; Ruiz, M.; Saligova, J.; Gutierrez-Sanchez, A.; Schlune, A.; Schulpis, K.; Serrano-Nieto, J.; Skarpalezou, A.; Skeath, R.; Slabbert, A.; Straczek, K.; Gizewska, M.; Terry, A.; Thom, R.; Tooke, A.; Tuokkola, J.; Dam, E. van; Hurk, T. A. M. van den; Ploeg, E. M. C. van der; Kerckhove, K. vande; Driessche, M. van; Wegberg, A. M. J. van; Wyk, K. van; Vasconcelos, C.; Velez Garcia, V.; Wildgoose, J.; Winkler, T.; Zolkowska, J.; Zuvadelli, J. und MacDonald, A.
(2018):
Early feeding practices in infants with phenylketonuria across Europe.
In: Molecular Genetics and Metabolism Reports, Bd. 16: S. 82-89
[PDF, 275kB]
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
2017
Kauffmann-Guerrero, Diego ORCID: https://orcid.org/0000-0003-1471-3290; Kahnert, Kathrin ORCID: https://orcid.org/0000-0001-9633-3368; Reu, S.; Jung, A.; Synyaeva, Z.; Mertsch, P. und Huber, R. M.
(2017):
NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy.
In: Annals of Oncology, Bd. 28
ORCID: https://orcid.org/0000-0003-1471-3290; Kahnert, Kathrin ORCID: https://orcid.org/0000-0001-9633-3368; Reu, S.; Jung, A.; Synyaeva, Z.; Mertsch, P. und Huber, R. M.
(2017):
NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy.
In: Annals of Oncology, Bd. 28
Brückl, W. M.; Wirtz, R. M.; Bertsch, T.; Ficker, J. H. und Jung, A.
(2017):
"Liquid biopsy": Analyse molekularer Marker aus Blutproben zur Therapiesteuerung beim Lungenkarzinom.
In: Pneumologie, Bd. 71, Nr. 3: S. 151-163
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Stintzing, S.; Price, B.; Knight, L.; McCavigan, A.; Walker, S.; Harkin, P.; Kennedy, R.; Neureiter, D.; Held, S.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 28
Heppt, M.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; Berking, C. und Flaig, M. J.
(2017):
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
In: Journal Der Deutschen Dermatologischen Gesellschaft, Bd. 15: S. 3
Böck, S.; Mehraein, Y.; Ormanns, S.; Kruger, S.; Westphalen, C. Benedikt; Haas, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
In: Annals of Oncology, Bd. 28, Nr. 2: S. 438-439
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
2016
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Dietmaier, W.; Merkelbach-Bruse, S.; Jung, A. und Lehmann, U.
(2016):
Bericht über die Sitzungen und die Mitgliederversammlung der AG Molekularpathologie.
In: Pathologe, Bd. 37: S. 249-252
Laurent-Puig, P.; Grisoni, M.-L.; Heinemann, V.; Fontaine, K.; Vazart, C.; Decaulne, V.; Rousseau, F.; Courtieu, B.; Lieabert, F.; Jung, A.; Neureiter, D.; Thiebaut, R. und Stintzing, S.
(2016):
MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial.
In: Annals of Oncology, Bd. 27
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
Stahler, A.; Stintzing, S.; Urbischek, M.; Modest, D. P.; Fischer von Weikersthal, L.; Kumbrink, J.; Heinemann, V.; Kirchner, T. und Jung, A.
(2016):
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
In: Annals of Oncology, Bd. 27
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
2015
Michl, M.; Heinemann, V.; Jung, A.; Engel, Jutta; Kirchner, T. und Neumann, J.
(2015):
Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
In: Pathology, Research and Practice, Bd. 211, Nr. 8: S. 601-609
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
2014
Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T. und Heinemann, V.
(2014):
Translational research in pancreatic cancer: KRAS and beyond.
In: Pancreas, Bd. 43, Nr. 1: S. 150-152
2013
Neumann, J.; Wehweck, L.; Maatz, S.; Engel, Jutta; Kirchner, T. und Jung, A.
(2013):
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
In: Virchows Archiv, Bd. 463, Nr. 4: S. 509-523
Modest, D. P.; Camaj, P.; Heinemann, V.; Schwarz, B.; Jung, A.; Laubender, Rüdiger P.; Gamba, S.; Haertl, C.; Stintzing, S.; Primo, S. und Bruns, C. J.
(2013):
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 6: S. 953-961
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T. und Heinemann, V.
(2013):
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
In: Journal of Gastroenterology, Bd. 48, Nr. 4: S. 544-548
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Vehling-Kaiser, U.; Winkelmann, C.; Fischer von Weikersthal, L.; Clemens, M. R.; Gauler, T. C.; Marten, A.; Klein, S.; Kojouharoff, G.; Barner, M.; Geissler, M.; Greten, T. F.; Mansmann, Ulrich; Kirchner, T. und Heinemann, V.
(2013):
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
In: British Journal of Cancer BJC, Bd. 108, Nr. 2: S. 469-476
2012
Schäfer, C.; Seeliger, H.; Bader, D. C.; Assmann, G.; Buchner, D.; Guo, Y.; Ziesch, A.; Palagyi, A.; Ochs, S.; Laubender, Rüdiger P.; Jung, A.; de Toni, E. N.; Kirchner, T.; Göke, Burkhard; Bruns, C. und Gallmeier, E.
(2012):
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
In: Journal of Cellular and Molecular Medicine, Bd. 16, Nr. 8: S. 1776-1791
Vogler, T.; Kriegl, L.; Horst, D.; Engel, Jutta; Sagebiel, S.; Schaffauer, A. J.; Kirchner, T. und Jung, A.
(2012):
The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors.
In: Experimental and Molecular Pathology, Bd. 92, Nr. 1: S. 111-117
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Neumann, J.; Horst, D.; Kriegl, L.; Maatz, S.; Engel, Jutta; Jung, A. und Kirchner, T.
(2012):
A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer.
In: Histopathology, Bd. 60, Nr. 3: S. 416-426
2011
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
Herbst, A.; Rahmig, K.; Stieber, P.; Philipp, A.; Jung, A.; Ofner, A.; Crispin, Alexander; Neumann, J.; Lamerz, R. und Kolligs, F. T.
(2011):
Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer.
In: American Journal of Gastroenterology, Bd. 106, Nr. 6: S. 1110-1118
2010
Kriegl, L.; Horst, D.; Engel, Jutta; Reiche, J. A.; Kirchner, T. und Jung, A.
(2010):
LEF1 and TCF4 expression correlate inversely with survival in colorectal cancer.
In: Journal of Translational Medicine, Bd. 8, Nr. 1: S. 123
Kriegl, L.; Jung, A.; Engel, Jutta; Jackstadt, R.; Gerbes, A. L.; Gallmeier, E.; Reiche, J. A.; Hermeking, H.; Rizzani, A.; Bruns, C. J.; Kolligs, F. T.; Kirchner, T.; Göke, Burkhard und de Toni, E. N.
(2010):
Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma.
In: Clinical Cancer Research, Bd. 16, Nr. 22: S. 5529-5538
2009
Horst, D.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2009):
Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
In: Cancer Investigation, Bd. 27, Nr. 8: S. 844-850
Horst, D.; Reu, S.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2009):
The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer.
In: Cancer, Bd. 115, Nr. 10: S. 2063-2070
Horst, D.; Kriegl, L.; Engel, Jutta; Jung, A. und Kirchner, T.
(2009):
CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
In: European Journal of Cancer, Bd. 45, Nr. 11: S. 2034-2040
2008
Horst, D.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2008):
CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
In: British Journal of Cancer BJC, Bd. 99, Nr. 8: S. 1285-1289